A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection

Breast Cancer Clinical Trial

Official title:

A Clinical Investigation (Multicentric, Single Arm, Prospective, Stratified) to Confirm the Ability of MammoWave (Microwave Mammogram) in Breast Lesions Detection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05300464
• Other study ID #: UBT 2022-01
• Status: Recruiting
• Phase: N/A
• Start date: January 7, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: May 2024
• Source: Umbria Bioengineering Technologies
• Contact: Gianluigi Tiberi
• Phone: 0039 34900564302
• Email: gianluigi[@]ubt-tech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicentric, single arm, prospective, stratified by breast density clinical investigation to confirm the ability of the microwave mammogram 'MammoWave' to detect breast lesions.

MammoWave is a innovative medical device, class IIa marked CE, which uses microwaves instead of ionazing radiation (x-ray) for breast lesions. Specifically MammoWave employs a novel technique wich generates images by processing very low power (<1mW) microwave.

The MammoWave exam takes few minutes for breast and is performed with the patient lying in a confortable facing down position.

MammoWave is safe to be used at any age, in any condition (pregnancy, specific illness and for unlimited number of times.

Description:

The maximum number of participants to the clinical investigation will be 600 (for all the sites). The study will be composed of two phases: a preliminary phase to 'optimize the imaging algorithm for each apparatus installed at each centre', where 15 volunteers (in each centre) having breast with no lesions (NL) will be examined by MammoWave. In the second phase, the remaining people will be enrolled (BL will be 50% of total) and examined by MammoWave by the clinical investigator, and results will be compared with the effective diagnosis already obtained by standard clinical methods. BL includes malignant lesions (BC) and benign lesions, and may be palpable or non-palpable lesions. BL includes also isolated clustered microcalcifications.

The primary gol of the clinical study is to assess MammoWave's ability in BL detection.

The study will involve investigational sites in Italy, Germany and Spain.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 600
• Est. completion date: December 31, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed Informed consent Form

• Women

• Adult = 18 years old

• Having a radiologist study output obtained using mammography within the last month. Such radiologist study output may be integrated with ultrasound and /or magnetic resonance imaging output if deemed necessary by the responsible investigator and when available. The radiological output will be integrated with histological one if deemed necessary by the responsible investigator and when available.

• Patients willing to comply with study protocol and recommendations

Exclusion Criteria:

• Patients who belong to any vulnerable group

• Patients with implanted electronic devices

• Patients who have undergone biopsy less than one week before MammoWave scan

• Patients with nipple piercings (unless they are removed prior to examination)

• Pregnancy or breastfeeding

Related Conditions & MeSH terms

• Breast Cancer

Intervention

Device:
• Clinical investigation medical device class IIa marked CE
Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients are ready for MammoWave exam. The exam will composed of two phases: the acquisition and data processing. During the acquisition that sholud takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.

Locations

Country	Name	City	State
Italy	Ospedale San Giovanni Battista - USL Umbria 2	Foligno	Perugia
Italy	IRCCS Policlinico San Martino	Genova
Spain	Hospital Universitario de Toledo	Toledo

Sponsors (1)

Lead Sponsor	Collaborator
Umbria Bioengineering Technologies

Countries where clinical trial is conducted

Italy,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MammoWave sensitivity (number of 'true positive' results)	MammoWave sensitivity (number of 'true positive' results) compared to Reference Standard	During the procedure
Secondary	MammoWave specificity and sensitivity	MammoWave specificity and sensitivity (against Reference Standard)	During the baseline
Secondary	Sensitivity for each breast density group	Sensitivity of MammoWave according to different types of breast density groups	During the baseline
Secondary	Sensitivity for patients which had recent mammography	Sensitivity for patients which had performed recently mammography exam	During the baseline
Secondary	Patient satisfaction questionnaire	Patient satisfaction questionnaire output according to their experience performing	During the baseline
Secondary	MammoWave sensitivity in BC	Sensitivity of MammoWave in Breast Cancer detection (against reference standard)	During the baseline)
Secondary	MammoWave specificity and sensitivity using RadioSpin simulator	Specificity and sensitivity of MammoWave (against Reference Standard) when retrospectively using MammoWave data in one RadioSpin technology simulator / Artificial Intelligence (AI) algorithms. NOTE: RadioSpin (Deep oscillatory neural networks computing and learning through the dynamics of RF neurons interconnected by RF spintronic synapses) is one of the projects funded by EU within the call FUTURE EMERGING TECHNOLOGIES (FET) H2020-FETPROACT. The RadioSpin project aims to build a hardware neural network, as a "Hardware Artificial Intelligence" will be implemented. During the project, these hardware neural networks will be optimized and tested on MammoWave data, being UBT partner of RadioSpin consortium (Grant agreement ID: 101017098)	During the Baseline